AZN241206C52000
- 14.85
- +0.35+2.41%
AstraZeneca Newsroom
AstraZeneca Appoints Iskra Reic as Executive Vice President, International
AstraZeneca Strengthens Leadership With New EVP Appointment
FTSE 100 Live 04 December: AstraZeneca Selling Hits Index, Rio Tinto Under Pressure to Review Listing
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Novo Nordisk and AstraZeneca Top of the 2025 Drug Picks for US Investment Bank - Read Why | NYSE:NVO
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca Hits 4-week High
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
AstraZeneca PLC ADR Falls Monday, Underperforms Market
AstraZeneca Announces Share Capital and Voting Rights
Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
USA Stock Market Outlook | Three major equity index futures rise together, US retailers prepare for Black Friday, the market will close 3 hours early on Friday.
On November 29 (Friday) during pre-market trading, all three major equity index futures in the U.S. rose.
Astrazeneca (AZN.US) Class 1 new drug approved for clinical trials in China for the first time, aiming to develop treatment for heart failure.
Astrazeneca (AZN.US) has received an implied license for clinical trials of its Class 1 new drug AZD5462 in china, which is intended for the treatment of heart failure.
AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
AstraZeneca's Breast Cancer Drug Wins State Insurance Coverage in China
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating